Clearly Opthea requires further funding to get to trial readout albeit the cash burn rate should start falling given the company is close to completing phase III trial enrolment. I am hopeful that under the new management structure some form of deal/partnership will be delivered which doesn’t result in significant dilution. If this occurs expect the share price to appreciate significantly.
Speaking of share numbers a bit of action in after hours trade with 3m going through in an after hours trade at the closing price of 75c. The share price is being strongly controlled at present. Something must give soon.
Ann: Opthea Appoints John Han, PharmD, as VP Medical Affairs, page-7
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
82.0¢ |
Change
-0.015(1.80%) |
Mkt cap ! $1.027B | |||
| Open | High | Low | Value | Volume |
| 82.0¢ | 82.5¢ | 81.0¢ | $238.6K | 291.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 20909 | 81.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 82.0¢ | 13042 | 5 |
View Market Depth
| Last trade - 10.41am 01/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |